UVA Researchers Identify Rev-RRE Axis as Key Mechanism in HIV Latency and Persistence

Scientists at the University of Virginia School of Medicine have identified a fundamental biological mechanism that explains why Human Immunodeficiency Virus (HIV) remains an incurable condition despite decades of medical advancement. The research, published by experts at the Myles H. Thaler Center for AIDS and Human Retrovirus Research, demonstrates that subtle genetic variations within a specific viral control system—the Rev-RRE axis—dictate the speed of viral replication and the ease with which the virus can re-emerge from its dormant state. These findings offer a new roadmap for developing "shock and kill" therapies, which aim to flush the virus out of hiding so it can be permanently eliminated from the body.

For over forty years, the medical community has sought a definitive cure for HIV, a pathogen that has claimed tens of millions of lives and continues to affect approximately 39 million people globally. While modern antiretroviral therapy (ART) can reduce the viral load to undetectable levels, allowing patients to lead long and healthy lives, the virus persists in a "latent" or sleeping state within the body’s immune cells. This latent reservoir remains invisible to both the immune system and current medications. The UVA study provides a critical explanation for why this reservoir is so difficult to clear, suggesting that the virus uses a biological "rheostat" to fine-tune its activity levels.

The Rev-RRE Axis: A Biological Dimmer Switch

The core of the UVA discovery lies in the interaction between a viral protein known as Rev and a complex RNA structure called the Rev Response Element (RRE). To replicate, HIV must transport its genetic instructions—encoded in RNA—from the nucleus of an infected human cell into the cytoplasm, where new viral particles are assembled. This transport process is facilitated by the Rev-RRE axis.

Historically, many researchers viewed this axis as a simple binary "on-off" switch. However, the UVA team, led by Patrick Jackson, MD, and Godfrey Dzhivhuho, PhD, discovered that the system functions more like a rheostat or a dimmer switch. Small mutations and variations in the genetic sequence of the RRE or the activity level of the Rev protein can subtly shift the intensity of viral production.

"Early on, many scientists thought that the Rev-RRE axis was merely an on-off switch for the virus," explained Marie-Louise Hammarskjold, MD, PhD, associate director of the Thaler Center. "However, our recent studies have shown that it functions more like a rheostat."

This variability means that even within a single patient, different "versions" of the virus may exist. Some versions may have high Rev-RRE activity, leading to aggressive replication, while others may have very low activity. Those with low activity are particularly dangerous from a clinical perspective because they are more likely to enter a deep state of latency, making them nearly impossible to detect or "wake up" using current experimental treatments.

The Evolution of HIV Treatment and the Persistence of the Reservoir

To understand the significance of the UVA findings, it is necessary to examine the chronology of HIV research and the evolution of treatment strategies.

1. The 1980s: The Crisis Era: HIV was identified as the cause of AIDS, and the focus was entirely on survival. The first drug, AZT, was approved in 1987, but it was often toxic and the virus quickly developed resistance.
2. The 1990s: The Breakthrough of ART: The introduction of Highly Active Antiretroviral Therapy (HAART) in 1996 revolutionized treatment. By using a "cocktail" of drugs, doctors could suppress the virus and prevent it from evolving resistance.
3. The Late 1990s to 2000s: Discovery of the Reservoir: Scientists realized that even when the virus was undetectable in the blood, it persisted in "latent reservoirs," primarily in resting CD4+ T cells. This meant that if a patient stopped taking ART, the virus would almost inevitably rebound within weeks.
4. The 2010s to Present: The Quest for a Cure: Research shifted toward "shock and kill" and "block and lock" strategies. "Shock and kill" involves using Latency Reversing Agents (LRAs) to wake the virus up so the immune system can kill the infected cells.

The UVA study explains why the "shock and kill" strategy has seen limited success in clinical trials. If a significant portion of the latent reservoir consists of viruses with low Rev-RRE activity, standard LRAs may not provide enough of a "shock" to overcome the biological inertia of the dimmer switch.

Data and Experimental Insights

The research conducted at UVA involved rigorous molecular analysis to determine how specific sequences of the Rev-RRE axis impacted viral behavior. The team utilized various viral strains to observe how changes in the RRE structure affected the export of viral RNA from the nucleus.

The data indicated a direct correlation between Rev activity levels and the "rebound" potential of the virus. In laboratory models, viruses engineered with high-activity Rev-RRE systems responded rapidly to chemical signals designed to end latency. Conversely, those with low-activity systems remained largely dormant, even when exposed to potent stimulants.

"We’ve known for some time that the Rev-RRE axis varied in activity," said David Rekosh, PhD, director of the Thaler Center. "This study links it directly to how well the virus can replicate and re-activate from latency."

This link provides a quantifiable metric for researchers. By analyzing the Rev-RRE sequence in a patient’s latent reservoir, clinicians might eventually be able to predict how difficult it will be to clear that patient’s infection, leading to more personalized and effective "cure" protocols.

Global Context: The Impact on High-Burden Regions

The implications of this research are particularly profound for regions like sub-Saharan Africa, which remains the epicenter of the global HIV epidemic. One of the study’s lead authors, Godfrey Dzhivhuho, PhD, brings a unique perspective to the research, having witnessed the impact of the virus firsthand in his home country of South Africa.

South Africa has the largest HIV epidemic in the world, with over 8 million people living with the virus. Dzhivhuho’s journey from the University of Venda to the University of Cape Town, and finally to the UVA Thaler Center, highlights the global collaborative effort required to solve the HIV puzzle.

"Coming from South Africa, where HIV affects so many lives, I’ve always wanted to be part of the effort to end this epidemic," Dzhivhuho said. "I hope this work brings us one step closer to a cure, not just by uncovering how the virus works, but by helping design smarter strategies to finally eliminate it."

His involvement underscores the importance of studying viral diversity. HIV is not a monolithic entity; it varies significantly across different geographical populations (clades). Understanding how the Rev-RRE axis functions across these different clades is essential for developing a cure that is effective globally, rather than just for specific subsets of the population.

Analysis of Implications: Moving Toward a "Smarter" Cure

The UVA findings suggest that the next generation of HIV therapies must be "smarter" and more nuanced. If the Rev-RRE axis is indeed a rheostat, then a "one-size-fits-all" approach to reversing latency is likely to fail.

1. Enhancing Latency Reversal:
Future "shock" therapies may need to include components that specifically target and enhance the Rev-RRE axis. By artificially boosting Rev activity or stabilizing the RRE structure, researchers might be able to "crank up" the rheostat, making the dormant virus more susceptible to detection.

2. Identifying the "Deep" Reservoir:
The study suggests that the most dangerous part of the latent reservoir is the "low-activity" segment. Diagnostic tools could be developed to measure the Rev-RRE activity in a patient’s reservoir cells, allowing doctors to gauge the "depth" of the latency they are fighting.

3. Refining Drug Development:
Pharmaceutical companies may need to pivot toward drugs that stabilize or manipulate RNA export pathways. While most current ART drugs target viral enzymes like reverse transcriptase, protease, or integrase, the UVA research highlights the nuclear export of RNA as a vulnerable—and currently under-targeted—step in the viral life cycle.

Conclusion and Future Outlook

The work performed at the University of Virginia School of Medicine marks a significant step forward in our understanding of HIV’s survival tactics. By shifting the focus to the Rev-RRE axis, Jackson, Hammarskjold, Rekosh, and Dzhivhuho have identified a critical lever that the virus uses to maintain its stealthy presence in the human body.

While a functional cure for HIV remains on the horizon rather than in the immediate future, this research provides the biochemical clarity needed to refine existing strategies. The transition from viewing HIV latency as a simple "on-off" state to a complex, adjustable "rheostat" allows for a more sophisticated approach to drug design.

As Dr. Patrick Jackson noted, "HIV treatment is lifesaving but also lifelong. Understanding how the virus stays latent in cells could help us develop a lasting cure." With the support of the Myles H. Thaler Research Support Gift and the National Institutes of Health, the team at UVA continues to probe the mysteries of the virus, driven by the goal of transforming HIV from a manageable chronic condition into a curable one. The journey from the laboratory bench to a clinical cure is long, but identifying the mechanism behind the virus’s "hiding act" is an essential milestone on that path.